Cathie Wood's ARK sells Roku and Tempus stock in latest trades

Cathie Wood's ARK ETFs continued their strategic portfolio rebalancing on Friday, significantly divesting from Roku (ROKU) and Tempus AI (TEM), offloading 22,732 ROKU shares and 60,550 TEM shares, extending a week-long pattern of reducing exposure to these companies. Concurrently, ARK demonstrated a bullish stance on biotech, consistently increasing holdings in firms like Arcturus Therapeutics, Atai Life Sciences, and Intellia Therapeutics, particularly through its ARKG fund. This selective selling and targeted buying indicate a broader strategy to reposition the ETFs towards perceived long-term growth opportunities in sectors like biotechnology and disruptive technology.

Analysis

ARK Invest's trading activity on September 19th reveals a continued and deliberate portfolio rebalancing, characterized by significant divestment from specific holdings and a concurrent accumulation in targeted growth sectors. The firm's flagship ARKK ETF extended its multi-day selling of Roku Inc. (ROKU), offloading another 22,732 shares valued at approximately $2.25 million, signaling a sustained bearish view on the streaming company. Similarly, ARK continued to reduce its exposure to Tempus AI Inc. (TEM), selling 60,550 shares for about $5.27 million, reinforcing a strategic shift away from the stock. In contrast, ARK is demonstrating strong conviction in the biotechnology space, with its ARKG ETF consistently acquiring shares in Arcturus Therapeutics (ARCT), Atai Life Sciences (ATAI), and Intellia Therapeutics (NTLA). This pattern of targeted buying suggests a bullish long-term bet on the genomics sector. The trading activity is more nuanced in other areas, with mixed signals in aerospace and defense—buying AeroVironment (AVAV) while having recently sold Kratos Defense (KTOS)—and continued selective investment in disruptive tech names like Baidu (BIDU) and Robinhood (HOOD). Overall, the flows indicate a clear rotation out of names like ROKU and TEM and into biotech and other specific technology companies perceived to have greater long-term potential.

Key Decisions for Investors

• Investors holding Roku (ROKU) and Tempus AI (TEM) should note the persistent selling pressure from a major thematic ETF, which could create near-term headwinds and reflects ARK's negative conviction.
• The consistent accumulation in biotech firms, specifically Arcturus Therapeutics (ARCT), Atai Life Sciences (ATAI), and Intellia Therapeutics (NTLA), signals strong institutional interest and may warrant further due diligence for those seeking long-term growth exposure to the genomics sector.
• Rather than viewing trades in isolation, investors should interpret ARK's activity as a strategic rotation, providing a signal on shifting sentiment within disruptive innovation, with capital currently favoring biotech over areas like streaming services.